The U.S. Food and Drug Administration said that certain sales materials for Johnson & Johnson’s epilepsy drug Topamax omit important risk information, in violation of the Federal Food, Drug, and Cosmetic Act, and asked the company to immediately cease the dissemination of them.
The agency said, in a letter sent to Johnson & Johnson unit Ortho-McNeil, […]